Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma

Cancer Genetics and Cytogenetics

Volumn 172, Issue 2, 2007, Pages 113-119

  Altungoz, Oguz ^a   Aygun, Nevim ^a   Tumer, Sait ^a   Ozer, Erdener ^a   Olgun, Nur ^a   Sakizli, Meral ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHI SQUARE TEST; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME BAND; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENETIC MARKER; HISTOLOGY; HUMAN; HUMAN TISSUE; MYCN GENE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845939529     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.10.005     Document Type: Article

References (51)

1. Cotterill S.J., Pearson A.D., Pritchard J., Foot A.B., Roald B., Kohler J.A., and Imeson J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 36 (2000) 901-908
2. Shimada H., Chatten J., Newton Jr. W.A., Sachs N., Hamoudi A.B., Chiba T., Marsden H.B., and Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73 (1984) 405-416
3. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17 (2005) 7-13
4. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 54 (2001) 897-910
5. Westermann F., and Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 184 (2002) 127-147
6. Brodeur G.M., Green A.A., Hayes F.A., Williams K.J., Williams D.L., and Tsiatis A.A. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41 (1981) 4678-4686
7. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., and Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305 (1983) 245-248
8. Brodeur G.M. Neuroblastoma: clinical significance of genetic abnormalities. Cancer Surv 9 (1990) 673-688
9. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3 (2003) 203-216
10. Brodeur G.M., Maris J.M., Yamashiro D.J., Hogarty M.D., and White P.S. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19 (1997) 93-101
11. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res 175 (1985) 105-113
12. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., and Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313 (1985) 1111-1116
13. Christiansen H., and Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 57 (1988) 121-126
14. Brodeur G.M., Sekhon G., and Goldstein M.N. Chromosomal aberrations in human neuroblastomas. Cancer 40 (1977) 2256-2263
15. Gilbert F., Balaban G., Moorhead P., Bianchi D., and Schlesinger H. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 7 (1982) 33-42
16. Mora J., Cheung N.K., Kushner B.H., LaQuaglia M.P., Kramer K., Fazzari M., Heller G., Chen L., and Gerald W.L. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2 (2000) 37-46
17. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24 (1995) 215-221
18. Gehring M., Berthold F., Edler L., Schwab M., and Amler L.C. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 55 (1995) 5366-5369
19. Maris J.M., White P.S., Beltinger C.P., Sulman E.P., Castleberry R.P., Shuster J.J., Look A.T., and Brodeur G.M. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55 (1995) 4664-4669
20. Martinsson T., Sjoberg R.M., Hedborg F., and Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 55 (1995) 5681-5686
21. White P.S., Maris J.M., Beltinger C., Sulman E., Marshall H.N., Fujimori M., Kaufman B.A., Biegel J.A., Allen C., and Hilliard C. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 92 (1995) 5520-5524
22. Schleiermacher G., Peter M., Michon J., Hugot J.P., Vielh P., Zucker J.M., Magdelenat H., Thomas G., and Delattre O. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10 (1994) 275-281
23. Takeda O., Homma C., Maseki N., Sakurai M., Kanda N., Schwab M., Nakamura Y., and Kaneko Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 10 (1994) 30-39
24. Caron H., Spieker N., Godfried M., Veenstra M., van Sluis P., de Kraker J., Voute P., and Versteeg R. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 30 (2001) 168-174
25. Ejeskar K., Sjoberg R.M., Abel F., Kogner P., Ambros P.F., and Martinsson T. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol 36 (2001) 61-66
26. Hogarty M.D., Liu X., Guo C., Thompson P.M., Weiss M.J., White P.S., Sulman E.P., Brodeur G.M., and Maris J.M. Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 35 (2000) 512-515
27. Maris J.M., Guo C., Blake D., White P.S., Hogarty M.D., Thompson P.M., Rajalingam V., Gerbing R., Stram D.O., Matthay K.K., Seeger R.C., and Brodeur G.M. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 36 (2001) 32-36
28. Martinsson T., Sjoberg R.M., Hallstensson K., Nordling M., Hedborg F., and Kogner P. Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 33 (1997) 1997-2001
29. White P.S., Thompson P.M., Seifried B.A., Sulman E.P., Jensen S.J., Guo C., Maris J.M., Hogarty M.D., Allen C., Biegel J.A., Matise T.C., Gregory S.G., Reynolds C.P., and Brodeur G.M. Detailed molecular analysis of 1p36 in neuroblastoma. Med Pediatr Oncol 36 (2001) 37-41
30. Bauer A., Savelyeva L., Claas A., Praml C., Berthold F., and Schwab M. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosomes Cancer 31 (2001) 228-239
31. Joshi V.V. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (modification of shimada classification). Pediatr Dev Pathol 3 (2000) 184-199
32. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., and Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86 (1999) 349-363
33. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., and Castleberry R.P. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 (1999) 364-372
34. Shimada H., Stram D.O., Chatten J., Joshi V.V., Hachitanda Y., Brodeur G.M., Lukens J.N., Matthay K.K., and Seeger R.C. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87 (1995) 1470-1476
35. Goto S., Umehara S., Gerbing R.B., Stram D.O., Brodeur G.M., Seeger R.C., Lukens J.N., Matthay K.K., and Shimada H. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92 (2001) 2699-2708
36. Ambros I.M., Benard J., Boavida M., Bown N., Caron H., Combaret V., Couturier J., Darnfors C., Delattre O., Freeman-Edward J., Gambini C., Gross N., Hattinger C.M., Luegmayr A., Lunec J., Martinsson T., Mazzocco K., Navarro S., Noguera R., O'Neill S., Potschger U., Rumpler S., Speleman F., Tonini G.P., Valent A., Van Roy N., Amann G., De Bernardi B., Kogner P., Ladenstein R., Michon J., Pearson A.D., and Ambros P.F. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21 (2003) 2077-2084
37. Joshi V.V., Cantor A.B., Altshuler G., Larkin E.W., Neill J.S., Shuster J.J., Holbrook C.T., Hayes F.A., and Castleberry R.P. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer 69 (1992) 2183-2196
38. Powell J.E., Esteve J., Mann J.R., Parker L., Frappaz D., Michaelis J., Kerbl R., Mutz I.D., and Stiller C.A. Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe. Lancet 352 (1998) 682-687
39. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
40. Brodeur G.M., Hayes F.A., Green A.A., Casper J.T., Wasson J., Wallach S., and Seeger R.C. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 47 (1987) 4248-4253
41. Olgun N., Kansoy S., Aksoylar S., Cetingul N., Vergin C., Oniz H., Sarialioglu F., Kantar M., Uysal K., Tuncyurek M., Kargi A., Aktas S., Bayol U., Karaca I., Arikan A., Balik E., Aktug T., Elmas N., Kovanlikaya A., Kinay M., Anacak Y., Degirmenci B., and Burak Z. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol. Pediatr Hematol Oncol 20 (2003) 211-218
42. Fong C.T., Dracopoli N.C., White P.S., Merrill P.T., Griffith R.C., Housman D.E., and Brodeur G.M. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 86 (1989) 3753-3757
43. Maris J.M., Weiss M.J., Guo C., Gerbing R.B., Stram D.O., White P.S., Hogarty M.D., Sulman E.P., Thompson P.M., Lukens J.N., Matthay K.K., Seeger R.C., and Brodeur G.M. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children' Cancer Group study. J Clin Oncol 18 (2000) 1888-1899
44. Takita J., Hayashi Y., Kohno T., Shiseki M., Yamaguchi N., Hanada R., Yamamoto K., and Yokota J. Allelotype of neuroblastoma. Oncogene 11 (1995) 1829-1834
45. Avigad S., Tamir Y., Yaniv I., Goshen J., Kaplinsky C., Cohen I.J., and Zaizov R. Genetic alterations involving chromosome 1p in children with neuroblastoma. Isr J Med Sci 30 (1994) 639-641
46. Caron H., van Sluis P., de Kraker J., Bokkerink J., Egeler M., Laureys G., Slater R., Westerveld A., Voute P.A., and Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334 (1996) 225-230
47. Spitz R., Hero B., Westermann F., Ernestus K., Schwab M., and Berthold F. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 34 (2002) 299-305
48. Kaneko Y., Kobayashi H., Maseki N., Nakagawara A., and Sakurai M. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants. Int J Cancer 80 (1999) 54-59
49. George R.E., Variend S., Cullinane C., Cotterill S.J., McGuckin A.G., Ellershaw C., Lunec J., and Pearson A.D. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol 36 (2001) 169-176
50. Freeman-Edward J., O'Neill S., Lastowska M., and Bown N. Expulsion of amplified MYCN from neuroblastoma tumor cells. Cancer Genet Cytogenet 116 (2000) 87-88
51. Valent A., Benard J., Clausse B., Barrois M., Valteau-Couanet D., Terrier-Lacombe M.J., Spengler B., and Bernheim A. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol 158 (2001) 1579-1584